SQZ Bio Stock (NYSE:SQZ)
Previous Close
$0.27
52W Range
$0.25 - $3.56
50D Avg
$0.55
200D Avg
$1.24
Market Cap
$12.83M
Avg Vol (3M)
$553.61K
Beta
2.71
Div Yield
-
SQZ Company Profile
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
SQZ Performance
Peer Comparison
| Ticker | Company |
|---|---|
| SNTI | Senti Biosciences, Inc. |
| NUVB | Nuvation Bio Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| FRTX | Fresh Tracks Therapeutics, Inc. |
| MNPR | Monopar Therapeutics Inc. |
| IKT | Inhibikase Therapeutics, Inc. |
| SABS | SAB Biotherapeutics, Inc. |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| FENC | Fennec Pharmaceuticals Inc. |
| HILS | Tharimmune, Inc. |
| ANTX | AN2 Therapeutics, Inc. |
| HOWL | Werewolf Therapeutics, Inc. |
| CADL | Candel Therapeutics, Inc. |
| PCSA | Processa Pharmaceuticals, Inc. |
| THRD | Third Harmonic Bio, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| LIPO | Lipella Pharmaceuticals Inc. |
| NLTX | Neurogene Inc. |
| KZR | Kezar Life Sciences, Inc. |